Kineta (KA) Stock Price, News & Analysis

Company Overview

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $0.56 to $0.83
• 50-Day Range: $0.56 to $0.83
• 52-Week Range: $0.33 to $5.39
• Volume: 481,083 shs
• Average Volume: 409,335 shs
• Market Capitalization: $7.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

Kineta Stock Analysis - MarketRank™

Kineta scored higher than 66% of companies evaluated by MarketBeat, and ranked 389th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Kineta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kineta has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kineta are expected to grow in the coming year, from ($1.41) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kineta is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kineta is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kineta has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.35% of the float of Kineta has been sold short.

Short Interest Ratio / Days to Cover

Kineta has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kineta has recently decreased by 68.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kineta does not currently pay a dividend.

Dividend Growth

Kineta does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.35% of the float of Kineta has been sold short.

Short Interest Ratio / Days to Cover

Kineta has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kineta has recently decreased by 68.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.72

News Sentiment

Kineta has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Kineta this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kineta insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.70% of the stock of Kineta is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.32% of the stock of Kineta is held by institutions.

KA Stock Analysis - Frequently Asked Questions

How have KA shares performed this year?

Kineta's stock was trading at $3.63 at the beginning of 2024. Since then, KA shares have decreased by 84.2% and is now trading at $0.5746.
View the best growth stocks for 2024 here.

How were Kineta's earnings last quarter?

Kineta, Inc. (NASDAQ:KA) posted its quarterly earnings data on Thursday, August, 8th. The company reported ($0.20) earnings per share for the quarter.

Who are Kineta's major shareholders?

Kineta's top institutional shareholders include PFG Investments LLC (2.67%). Insiders that own company stock include Shawn Iadonato, Craig W Philips, Thierry Guillaudeux, Pauline Kenny, Raymond J Bartoszek and Keith Baker.
View institutional ownership trends.

How do I buy shares of Kineta?

Shares of KA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/08/2024
• Today: 9/18/2024
• Next Earnings (Estimated): 11/01/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KA
• CUSIP: N/A
• CIK: 1445283
• Web: www.kinetabio.com
• Phone: (206) 378-0400
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +1,292.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,100,000.00
• Net Margins: N/A
• Pretax Margin: -345.77%
• Return on Equity: -1,044.95%
• Return on Assets: -336.46%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 0.14
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: $5.44 million
• Price / Sales: 1.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 1.98

Miscellaneous

• Outstanding Shares: 12,260,000
• Free Float: 9,350,000
• Market Cap: $7.04 million
• Optionable: Not Optionable
• Beta: 0.46